Amicus Therapeutics Announces Presentation and Posters at the SSIEM Annual Symposium 2023
PHILADELPHIA, Aug. 29, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: FOLD), today announced that one oral presentation and five posters across its development programs will be included at the , being held August 29 – September 1, 2023 in Jerusalem, Israel.
Oral Presentation:
Pompe Disease:
Abstract Title: Switching treatment from alglucosidase alfa to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease
- Presenter: Priya Kishnani, MD, MBBS, Duke University Medical Center, Durham, NC, U.S.A.
- Session: Clinical Studies & Outcomes I
- Date and time: Wednesday, August 30, 8:45-9:00 a.m. I.D.T.
- Location: Oren 2
Poster Sessions:
Fabry Disease:
Abstract Title: Multiorgan involvement in females with Fabry disease: results from two phase III trials and the followME registry (Poster #B169)
- Presenter: Peter Nordbeck, MD, University Hospital Würzburg, Würzburg, Germany
- Location: Exhibit Hall
Abstract Title: Exploring the Experiences of Females Living with Fabry Disease in Canada (Poster #B12)
- Presenter: Julia Alton, Executive Director, Canadian Fabry Association, Ontario, Canada
- Location: Exhibit Hall
Pompe Disease:
Abstract Title: 104-week efficacy and safety of cipaglucosidase alfa plus miglustat in patients with late-onset Pompe disease previously treated with alglucosidase alfa (Poster #B167)
- Presenter: Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
- Location: Exhibit Hall
Abstract Title: Safety of home administration of cipaglucosidase alfa plus miglustat in late-onset Pompe disease: results from multiple clinical trials (Poster #B20)
- Presenter: Ozlem Goker-Alpan, MD, Lysosomal and Rare Disorders Research and Treatment Center, Fairfax, VA, U.S.A
- Location: Exhibit Hall
Abstract Title: Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL (Poster #B168)
- Presenter: Tahseen Mozaffar, MD, Department of Neurology, University of California, Irvine, CA, U.S.A.
- Location: Exhibit Hall
For more information on the SSIEM Annual Symposium 2023, please visit .
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at , and follow on and .
CONTACTS:
Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
(609) 662-3809
Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
(609) 662-5079
FOLD–G
